Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 3/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4423792 | 0.84 | MIF (0.42) | CA12CA1CA7CA14CTSS | |
| SCHEMBL6820222 | 0.83 | MAOB (0.45) | CA12CA1CA7CA14IDO1 | |
| SCHEMBL6820227 | 0.83 | MAOB (0.45) | CA12CA1CA7CA14IDO1 | |
| SCHEMBL27686453 | 0.81 | PPARA (0.45) | PPARAPPARGMAPTCYP2C19CYP3A4 | |
| SCHEMBL294028 | 0.79 | MAOB (0.43) | CA1MAPTRAB9AALDH1A1CYP2C19 | |
| Phenylacetaldehyde SCHEMBL28513708 | 0.79 | CA12 (0.44) | CA12CA1CA7CA14IDO1 | |
| SCHEMBL28120689 | 0.78 | MAOB (0.40) | CA12CA1CA7CA14IDO1 | |
| SCHEMBL27041579 | 0.77 | CTSS (0.43) | IDO1MAPTALDH1A1CYP2C19CTSS | |
| SCHEMBL4645707 | 0.76 | ALDH1A1 (0.48) | ALDH1A1CYP2C19MAOBHCAR2CYP2C9 | |
| SCHEMBL290693 | 0.76 | MAPT (0.51) | MAPTALDH1A1HCAR2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2897940-B1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2019-05-01 | — | — | EP | claimed |
| EP-2299813-B1 | BRANCHED 3- AND 6-SUBSTITUTED QUINOLINES AS CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2015-12-16 | — | — | EP | claimed |
| US-8377955-B2 | Branched 3- and 6-substituted quinolines as CGRP receptors antagonists | Merck, Sharp & Dohme, Corp. (US) | 2013-02-19 | — | — | US | claimed |
| US-20110105549-A1 | BRANCHED 3- AND 6-SUBSTITUTED QUINOLINES AS CGRP RECEPTORS ANTAGONISTS | MERCK SHARP & DOHME LLC | 2011-05-05 | — | — | US | claimed |
| EP-1572678-A4 | SUBSTITUTED N-PHENYL SULFONAMIDE BRADYKININ ANTAGONISTS | ELAN PHARM INC (US) | 2008-05-07 | — | — | EP | claimed |
| US-7183281-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-27 | — | — | US | claimed |
| US-7074783-B2 | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2006-07-11 | — | — | US | claimed |
| EP-1572678-A2 | SUBSTITUTED N-PHENYL SULFONAMIDE BRADYKININ ANTAGONISTS | Elan Pharmaceuticals, Inc. (US) | 2005-09-14 | — | — | EP | claimed |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | claimed |
| US-20040138208-A1 | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | claimed |
| WO-2004056319-A2 | SUBSTITUTED N-PHENYL SULFONAMIDE BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS INC. (US) | 2004-07-08 | — | — | WO | claimed |
| EP-2897940-B1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2019-05-01 | — | — | EP | disclosed |
| CN-108456154-A | A kind of preparation method of N- tertbutyloxycarbonyls alkyl guanidine | 昆明理工大学 | 2018-08-28 | — | — | CN | disclosed |
| EP-2299813-B1 | BRANCHED 3- AND 6-SUBSTITUTED QUINOLINES AS CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2015-12-16 | — | — | EP | disclosed |
| EP-2897940-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | Boehringer Ingelheim International GmbH (DE) | 2015-07-29 | — | — | EP | disclosed |
| WO-2004098590-A1 | 4-BROMO-5- (2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (1-(AMINOCARBONYL) ETH-1-YL) AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| US-20040138208-A1 | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2004056319-A2 | SUBSTITUTED N-PHENYL SULFONAMIDE BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004033436-A1 | SULFONYLBENZODIAZEPINONE ACETAMIDES AS BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS INC (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105549-A1 | BRANCHED 3- AND 6-SUBSTITUTED QUINOLINES AS CGRP RECEPTORS ANTAGONISTS | GALR3, BDKRB2, CCKBR | CA12 4324/4885CA1 4317/4885CA7 2995/4885 |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | BDKRB2, BDKRB1, PDXK | CA12 2479/4885CA1 1006/4885CA7 1840/4885 |
| US-20040138208-A1 | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists | BDKRB1, BDKRB2, HRH2 | CA12 2983/4885CA1 1803/4885CA7 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.